Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTINE B FRANZESE

Allopathic & Osteopathic Physicians Otolaryngology Otolaryngic Allergy

NPI
1932171352
CMS profile
314141
Location
COLUMBIA, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$90,493.75

170 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTINE B FRANZESE

NPI 1932171352 · CMS profile ID 314141

Allopathic & Osteopathic Physicians / Otolaryngology / Otolaryngic Allergy

COLUMBIA, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932171352?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTINE B FRANZESE, NPI 1932171352, CMS profile ID 314141. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932171352?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). CHRISTINE B FRANZESE, NPI 1932171352, CMS profile ID 314141. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932171352?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
CHRISTINE B FRANZESE, NPI 1932171352, CMS profile ID 314141, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1932171352?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

170 matching records · $90,493.75 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 170 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 170.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $17.3405/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019862365 CMS
GlaxoSmithKline, LLC. $2,400.0005/10/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003172177 CMS
GENZYME CORPORATION $35.1205/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050017345 CMS
GlaxoSmithKline, LLC. $4,000.0005/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003172171 CMS
GlaxoSmithKline, LLC. $1.3804/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003173149 CMS
GlaxoSmithKline, LLC. $13.1004/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003172183 CMS
Pharming Healthcare, Inc. $18.6104/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029331799 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.0804/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055388263 CMS
GlaxoSmithKline, LLC. $364.4004/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003171063 CMS
GlaxoSmithKline, LLC. $25.0004/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003171093 CMS
GlaxoSmithKline, LLC. $10.0004/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003171099 CMS
GlaxoSmithKline, LLC. $25.0004/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003172227 CMS
GlaxoSmithKline, LLC. $405.9804/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003173155 CMS
GlaxoSmithKline, LLC. $25.0004/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003173167 CMS
GlaxoSmithKline, LLC. $20.0004/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003173177 CMS
AstraZeneca Pharmaceuticals LP $14.8304/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015420287 CMS
Optinose US, Inc. $0.3304/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035123089 CMS
Optinose US, Inc. $19.3804/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035123179 CMS
Pharming Healthcare, Inc. $19.4504/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029331789 CMS
BioCryst US Sales Co., LLC $23.3804/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012586009 CMS
Regeneron Healthcare Solutions, Inc. $37.2304/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999176751 CMS
Genentech USA, Inc. $20.1203/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040328165 CMS
GlaxoSmithKline, LLC. $117.7403/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003172193 CMS
Amgen Inc. $20.8603/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019862361 CMS
GENZYME CORPORATION $122.1103/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050017279 CMS
GENZYME CORPORATION $5,640.0003/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050017283 CMS
GlaxoSmithKline, LLC. $22.6003/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003172205 CMS
Grifols USA, LLC $15.0603/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011870839 CMS
Optinose US, Inc. $1,500.0003/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035123569 CMS
AstraZeneca Pharmaceuticals LP $2,150.0003/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011743747 CMS
AstraZeneca Pharmaceuticals LP $14.4603/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014573953 CMS
GENZYME CORPORATION $18.5603/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050017267 CMS
AstraZeneca Pharmaceuticals LP $93.9303/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011383743 CMS
GlaxoSmithKline, LLC. $6,400.0003/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003172277 CMS
Inspire Medical Systems, Inc. $114.6703/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058783517 CMS
CSL Behring $18.1002/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043067375 CMS
GlaxoSmithKline, LLC. $1,200.0002/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003172245 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.2902/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055388261 CMS
GlaxoSmithKline, LLC. $4,800.0002/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003171031 CMS
GlaxoSmithKline, LLC. $2,400.0002/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003171059 CMS
GlaxoSmithKline, LLC. $4,800.0002/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003172261 CMS
Regeneron Healthcare Solutions, Inc. $121.8102/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999176747 CMS
AstraZeneca Pharmaceuticals LP $20.6302/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014183997 CMS
AstraZeneca Pharmaceuticals LP $19.8802/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015941541 CMS
GlaxoSmithKline, LLC. $20.3802/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003173137 CMS
GlaxoSmithKline, LLC. $13.0802/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003171053 CMS
GlaxoSmithKline, LLC. $65.0002/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003169993 CMS
GlaxoSmithKline, LLC. $25.0002/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003171037 CMS
GlaxoSmithKline, LLC. $320.9202/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003171071 CMS
GlaxoSmithKline, LLC. $983.8602/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003172189 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $106,112.53 118
PY2020 $43,386.75 63
PY2021 $108,853.88 114
PY2022 $133,428.60 147
PY2023 $90,493.75 170
PY2024 $90,387.48 112
PY2025 $159,129.73 101

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $163,934.09 69
PY2024 Principal investigator $227,904.63 146
PY2023 Recipient $1,718.06 7
PY2023 Principal investigator $287,213.84 112
PY2022 Principal investigator $204,633.19 55
PY2021 Principal investigator $218,854.35 37
PY2020 Recipient $3,766.72 2
PY2020 Principal investigator $190,041.80 51
PY2019 Principal investigator $247,329.99 103

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

69 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.99 12/24/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.82 12/24/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.20 12/24/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.99 12/24/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $34.06 12/24/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.99 12/24/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $51.09 12/24/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.85 12/24/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.75 12/24/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,620.00 12/24/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $450.00 12/24/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.87 12/24/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139061
Principal investigator 1 GlaxoSmithKline, LLC. $4,329.00 12/19/2025 Non-covered Recipient Entity
THE CURATORS OF THE UNIVERSITY OF MISSOURI
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192142439
Principal investigator 1 Eli Lilly and Company $19,430.00 12/03/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS No dispute reported 06/30/2026 1187871731
Principal investigator 1 GlaxoSmithKline, LLC. $5,205.60 11/25/2025 Non-covered Recipient Entity
THE CURATORS OF THE UNIVERSITY OF MISSOURI
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192142428
Principal investigator 1 GlaxoSmithKline, LLC. $2,663.10 10/17/2025 Non-covered Recipient Entity
THE CURATORS OF THE UNIVERSITY OF MISSOURI
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192136411
Principal investigator 1 GlaxoSmithKline, LLC. $5,313.60 10/02/2025 Non-covered Recipient Entity
THE CURATORS OF THE UNIVERSITY OF MISSOURI
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192142433
Principal investigator 1 Novartis Pharmaceuticals Corporation $370.28 10/01/2025 Non-covered Recipient Entity
ENT AND ALLERGY CENTER OF MISSOURI
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190305341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.75 09/08/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184139033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.75 09/08/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184139035
Principal investigator 1 GlaxoSmithKline, LLC. $5,480.10 09/03/2025 Non-covered Recipient Entity
THE CURATORS OF THE UNIVERSITY OF MISSOURI
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192136431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $34.06 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.87 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.20 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.82 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $34.06 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.99 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.99 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184139029
Principal investigator 1 GlaxoSmithKline, LLC. $4,406.40 08/04/2025 Non-covered Recipient Entity
THE CURATORS OF THE UNIVERSITY OF MISSOURI
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192142423
Principal investigator 1 GlaxoSmithKline, LLC. $20,826.99 07/23/2025 Non-covered Recipient Entity
THE CURATORS OF THE UNIVERSITY OF MISSOURI
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192145151
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,199.00 07/02/2025 Covered Recipient Teaching Hospital
Univ Of Missouri Health Care
A Multicentre Single-Arm Phase 3b Study to Assess Changes in Symptoms in Adult Participants with Chronic Rhinosinusitis with Nasal Polyposis Initiating Treatment with Tezepelumab (ESSENCE) No dispute reported 06/30/2026 1185547475
Principal investigator 1 GENZYME CORPORATION $7,483.00 07/02/2025 Covered Recipient Teaching Hospital
Univ Of Missouri Health Care
A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients No dispute reported 06/30/2026 1226088706
Principal investigator 1 GlaxoSmithKline, LLC. $4,771.80 06/20/2025 Non-covered Recipient Entity
THE CURATORS OF THE UNIVERSITY OF MISSOURI
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192145147
Principal investigator 1 GlaxoSmithKline, LLC. $6,037.20 05/21/2025 Non-covered Recipient Entity
THE CURATORS OF THE UNIVERSITY OF MISSOURI
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192136425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.75 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.75 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.75 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.77 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.75 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.75 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.75 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.34 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.50 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.75 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.75 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.34 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.75 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.75 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.75 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.34 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.20 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.20 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.75 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $655.00 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.34 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.75 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184139001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.35 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184139003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.75 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184139005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.75 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184139007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.20 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184139009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $393.07 04/28/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138957
Principal investigator 1 GlaxoSmithKline, LLC. $3,216.60 04/23/2025 Non-covered Recipient Entity
THE CURATORS OF THE UNIVERSITY OF MISSOURI
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192136417
Principal investigator 1 GlaxoSmithKline, LLC. $4,454.71 02/27/2025 Non-covered Recipient Entity
THE CURATORS OF THE UNIVERSITY OF MISSOURI
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1192145138
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $672.03 02/27/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138949
Principal investigator 1 GlaxoSmithKline, LLC. $8,354.70 02/25/2025 Non-covered Recipient Entity
THE CURATORS OF THE UNIVERSITY OF MISSOURI
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192136436
Principal investigator 1 GENZYME CORPORATION $12,478.00 02/10/2025 Covered Recipient Teaching Hospital
Univ Of Missouri Health Care
A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients No dispute reported 06/30/2026 1226088700
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $393.07 01/31/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138937
Principal investigator 1 GlaxoSmithKline, LLC. $6,424.20 01/24/2025 Non-covered Recipient Entity
THE CURATORS OF THE UNIVERSITY OF MISSOURI
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192145143
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,599.71 01/03/2025 Covered Recipient Teaching Hospital
Univ Of Missouri Health Care
A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT No dispute reported 06/30/2026 1185547473